N
BHVN

Natixis’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Natixis’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-32,429
Closed -$2.11M – 1140
2020
Q3 		$2.11M Sell
32,429
-17,360
-35% -$1.14M 0.02% 408
2020
Q2 		$3.64M Buy
+49,789
New +$2.65M 0.03% 337

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Natixis's BHVN Position: Q4 2020 in Review

Natixis sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2020, closing a stake of 32,429 shares — an estimated $2.11M sold.

Natixis first reported a position in BHVN in Q2 2020 and held it in 2 quarters. The position peaked at $3.64M in Q2 2020. 238 funds tracked by Wall St. Rank hold BHVN as of Q4 2020.

  • Natixis reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2020 after selling out during the quarter.
  • Natixis sold 32,429 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2020, an estimated $2.11M.
  • Natixis first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 2 quarters.
  • Natixis's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.64M in Q2 2020.
  • 238 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2020.

Based on Natixis's 13F filing for Q4 2020, filed 12 Feb 2021.